Instil Bio, Inc. announced a strategic update. Instil has entered into an agreement with a collaborator that has a successful track record of manufacturing and dosing patients with cell therapies to conduct preclinical manufacturing feasibility studies in the ITIL-306 program. With the objective of saving costs and improving time efficiency, the company is announcing the closure of its UK manufacturing and clinical operations, thereby reducing its UK workforce which is expected to be substantially completed by the first half of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.88 USD | +0.68% | +5.60% | +55.91% |
May. 13 | Baird Adjusts Price Target on Instil Bio to $32 From $54, Maintains Outperform Rating | MT |
May. 10 | Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.91% | 76.75M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- TIL Stock
- News Instil Bio, Inc.
- Instil Bio, Inc. Announces the Closure of Its UK Manufacturing and Clinical Operations